[ad_1]
The two companies said a recent analysis of Israeli data shows the vaccine to be 97% effective in preventing symptomatic infections, serious illness and death.
This corresponds to the 95% efficacy rate announced at the end of the final phase trials of the vaccine last December.
Israel’s health ministry, which works with health authorities providing the vaccine, said in an emailed statement that the data is based on its system to track the spread of the infection.
The ministry had previously said that the “Pfizer Bionic” vaccine reduced Corona virus infection among asymptomatic cases by 89.4% and 93.7% in symptomatic cases, according to data collected between Jan. 17 and Jan. February 6.
Albert Burla, CEO of “Pfizer”, said the data is important to the company “because it means that few people pass the virus on to others without knowing it”.
The analysis also showed the vaccine’s effectiveness in preventing the rapidly spreading viral strain discovered in Britain, noting that more than 80% of the samples tested belonged to this strain.
According to data from the Israeli Ministry of Health, about 55 percent of the population of 9 million people received at least one dose of the “Pfizer Bionic” vaccine, adding that 43 percent received both doses.
Weizmann Institute of Science researcher Iran Segal said Israel had recorded 71% fewer deaths and 55% fewer injuries, compared to the peak recorded in mid-January.
[ad_2]
Source link
